Background Dravet syndrome is a rare, treatment-resistant developmental epileptic
encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has …

Physicians and other healthcare professionals may often be faced with the need to change
opioids during the course of a patient's opioid analgesic care due to a number of clinical …

The safety, tolerability, and efficacy of the lidocaine patch 5% (Lidoderm®), a targeted peripheral
analgesic with an FDA‐approved indication for the treatment of postherpetic neuralgia, …

Background: Population mean changes from clinical trials are difficult to apply to individuals
in clinical practice. Responder analysis may be better, but needs validating for level of …

Importance New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS),
a profoundly impairing, treatment-resistant, developmental and epileptic …

The Neuropathic Pain Scale (NPS) is a valid measure of the pain qualities and perceived
depth of neuropathic pain. However, it does not include a number of pain qualities commonly …

The distinction between neuropathic and non-neuropathic pain reflects partially distinct
mechanisms and patterns of treatment response. It was therefore hypothesized that patients with …

… Methods The methods used in this study are similar to those previously published by
Gammaitoni and Davis.The protocol and informed consent forms for this study were reviewed and …

Objective: To determine the impact of the lidocaine patch 5% on pain qualities associated
with chronic pain from post-herpetic neuralgia (PHN), painful diabetic neuropathy (DN), and …

Purpose To assess the impact of fenfluramine (FFA) on the expected mortality incidence,
including sudden unexpected death in epilepsy (SUDEP), in persons with Dravet syndrome (DS…